Active clinical trials of the Pediatric Early Clinical Trials East Network.
Please find here an overview of our current clincical trial portfolio.
If you are interested in participating in a specific study,
Active clinical trials of the Research Network
On this page you will find an overview of our currently active studies. If you are interested in participating in a specific study, please email the contact person at the respective clinics. You will find the contact information via the respective link to the website of the respective study locations.
Leukemias
Indication: CD22+ relapsed/refractory BCP-ALL
Phase: II
Protocol Nr.: ITTC-059 / NTR5736
EudraCT/NCT-Nr.: EudraCT2016-000227-71
Trial location: Berlin, Charité
Investigational drug: Midostaurin
Indication: FLT3pos AML
Phase: II
Protocol Nr.: CPKC412A2218
EudraCT/NCT-Nr.: EudraCT2017-004830-28
Trial location: Berlin, Charité
Indikation: Relapsed or refractory pediatric AML
Phase: Ib
Prüfplan-Nr.: ITCC-092-VyClo
EudraCT/NCT-Nr.: EudraCT2020-000142-34
Studienstandort: Berlin, Charité
Investigational drug: Cellgene JCAR
Indication: B-ALL + B-NHL
Phase: I/II
Protocol Nr.: JCAR017-BCM-004
EudraCT/NCT-Nr.: EudraCT2018-001246-34
Trial location: Berlin, Charité
Investigational drug: MB-CART19.1
Indication: B-ALL REZ
Phase: II/III
Protocol Nr.: M-2017-322
EudraCT/NCT-Nr.: EudraCT2017‐002848‐32
Trial location: Berlin, Charité
Indikation: ALL
Phase: III
Prüfplan-Nr.: Inotuzumab vers. R3
EudraCT/NCT-Nr.: EudraCT2022-000186-40
Studienstandort: Berlin, Charité
Lymphomas
Investigational drug: Brigatinib
Indication: ALK+ ALCL, Solid Tumors, IMT
Phase: I/II
Protocol Nr.: ITCC-098 Briga Ped
EudraCT/NCT-Nr.: EudraCT2021-002713-34
Trial location: Berlin, Charité
Indikation: Malignancies carrying a genetic alteration of ALK, MET or ROS1
Phase: Ib
Prüfplan-Nr.: ITCC-053 CRISP
EudraCT/NCT-Nr.: EudraCT2015‐005437‐53
Studienstandort: Berlin, Charité
Investigational drug: Cellgene JCAR
Indication: B-ALL + B-NHL
Phase: I/II
Protocol Nr.: JCAR017-BCM-004
EudraCT/NCT-Nr.: EudraCT2018-001246-34
Trial location: Berlin, Charité
Investigational drug: Pembrolizumab
Indication: Hodgkin Lymphoma
Phase: II
Protocol Nr.: Keynote 667
EudraCT/NCT-Nr.: EudraCT2017-001123-53
Trial location: Berlin, Charité
Solid Tumors
Indication: Relapsed/Refractory Solid Tumors
Phase: I/II
Protocol Nr.: JP04
EudraCT/NCT-Nr.: NCT05440786
Trial location: Berlin, Charité
Investigational drug: Brigatinib
Indication: ALK+ ALCL, Solid Tumors, IMT
Phase: I/II
Protocol Nr.: ITCC-098 Briga Ped
EudraCT/NCT-Nr.: EudraCT2021-002713-34
Trial location: Berlin, Charité
Indikation: V600 Mutationen
Phase: IV
Prüfplan-Nr.: CDRB436G2401
EudraCT/NCT-Nr.: EudraCT2018-004459-19
Studienstandort: Berlin, Charité
Investigational drug: Larotrectinib
Indication: Solid Tumors
Phase: I/II
Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)
EudraCT/NCT-Nr.: EudraCT2016-003498-16
Trial location: Berlin, Charité
Indication:
Phase: I/II
Protocol-Nr.: GlaxoSmithKline
EudraCT/NCT-Nr.: on hold
Trial location: Berlin, Charité
Indication: Relapsed/Refractory Solid Tumors
Phase: Ib
Protocol Nr.: I3Y-MC-JPCS
EudraCT/NCT-Nr.: EudraCT2019-002931-27
Trial location: Berlin, Charité
Indikation: Malignancies carrying a genetic alteration of ALK, MET or ROS1
Phase: Ib
Prüfplan-Nr.: ITCC-053 CRISP
EudraCT/NCT-Nr.: EudraCT2015‐005437‐53
Studienstandort: Berlin, Charité
Indication: Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
Phase: I/II
Protocol Nr.: FireFly DAY 101
EudraCT/NCT-Nr.: EudraCT2020-003657-30
Trial location: Berlin, Charité
Investigational drug: Nivolumab + Entinostat
Indication: Refractory high risk malignoma
Phase: I/II
Protocol Nr.: INFORM2 NivEnt
EudraCT/NCT-Nr.: EudraCT2018-000127-14
Trial location: Berlin, Charité
Investigational drug: MiNivAn (131-1 mIBG/Nivolumab/ch14.18/CHO antibody in r/r neuroblastoma)
Indication: refraktory or recurrent high risk neuroblastomas with MIBG avidity to investigate the combination of 131-I-mIBG therapy followed by ch14.18/CHO and Nivolumab
Phase: I
Protocol-Nr.: RHM CHI0811
EudraCT/NCT-Nr.: 2016-002221-11
Trials location: Greifswald
ZNS Tumors
Indication: Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
Phase: I/II
Protocol Nr.: FireFly DAY 101
EudraCT/NCT-Nr.: EudraCT2020-003657-30
Trial location: Berlin, Charité
Investigational drug: Larotrectinib
Indication: Solid Tumors
Phase: I/II
Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)
EudraCT/NCT-Nr.: EudraCT2016-003498-16
Trial location: Berlin, Charité
Indikation: pan RAFi
Phase: III
Prüfplan-Nr.: FireFly DAY 102
EudraCT/NCT-Nr.: EudraCT2022-001363-27
Studienstandort: Berlin, Charité
Investigational drug: Selumetinib
Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)
Phase: I/II
Protocol Nr.: SPRINKLE D1346C00004
EudraCT/NCT-Nr.: EudraCT2020-005608-20
Trial location: Berlin, Charité
Other deseases
Investigational drug: CDZ173/Leniolisib
Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)
Phase: II/III
Protocol Nr.: CCDZ173X2201
EudraCT/NCT-Nr.: EudraCT2016-000468-41
Trial location: Dresden
Indikation: Chemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantation
Phase: III
Prüfplan-Nr.: TRACE
EudraCT/NCT-Nr.: EudraCT2018-000853-29
Studienstandort: Berlin, Charité
Investigational drug: Crizanlizumab
Indication: Sickel cell disease
Phase: II
Protocol Nr.: CSEG 101B2201
EudraCT/NCT-Nr.: EudraCT2017-001747-12
Trial location: Berlin, Charité